MacEwan MR, MacEwan S, Kovacs TR, Batts J, et al.
Cureus. Date of publication 2017 Oct 2;volume 9(10):e1736.
1. Cureus. 2017 Oct 2;9(10):e1736. doi: 10.7759/cureus.1736.
What Makes the Optimal Wound Healing Material? A Review of Current Science and
Introduction of a Synthetic Nanofabricated Wound Care Scaffold.
MacEwan MR(1), MacEwan S(1), Kovacs TR(1), Batts J(2).
Author information:
(1)Research & Development, Acera Surgical, Inc.
(2)Research, Telos Partners, Llc.
Wound matrix materials are used to improve the regeneration of dermal and
epidermal layers in both acute and chronic wounds. Contemporary wound matrices
are primarily composed of biologic materials such as processed xenogeneic and
allogeneic tissues. Unfortunately, existing biologic wound matrices possess
multiple limitations including poor longevity, durability, strength, and
enzymatic resistance required for persistent support for new tissue formation. A
fully-synthetic, resorbable electrospun material (Restrata Wound Matrix, Acera,
St.Louis, Missouri ) that exhibits structural similarities to the native
extracellular matrix offers a new approach to the treatment of acute and chronic
wounds. This novel matrix is the first product to combine the advantages of
synthetic construction (e.g. resistance to enzymatic degradation, excellent
biocompatibility, strength/durability and controlled degradation) with the
positive attributes of biologic materials (e.g. biomimetic architecture similar
to human extracellular matrix (ECM), fibrous architecture optimized to support
cellular migration and proliferation, engineered porosity to encourage tissue
ingrowth and vascularization). These features allow RWM to achieve rapid and
complete healing of full-thickness wounds that, in preclinical studies, is
comparable to Integra Bilayer Wound Matrix (Integra LifeSciences, Plainsboro,
New Jersey), a gold standard biologic material with diverse clinical indications
in the wound care. Together, this review suggests that the RWM offers a unique
fully-synthetic alternative to existing biologic matrices that is effective,
widely available, easy to store, simple to apply and low cost.
DOI: 10.7759/cureus.1736
PMCID: PMC5711514
PMID: 29209583
Conflict of interest statement: Matthew MacEwan is the patent holder for the
technology discussed in this review (Restrata Wound Matrix, Acera Surgical)
